How did we go from one amyloid failure to a dozen?
(ALEX HOGAN/STAT)
At this point, everyone knows that targeting plaques called beta-amyloids has, despite the drug industry’s best efforts, never resulted in an actual drug for Alzheimer’s disease. But what convinced pharma to keep trying despite so many failures?
We dug through the history, and the answer is a little more complicated than you might think.
Join us for a brief, animated journey through the history of Alzheimer’s research to understand why the amyloid hypothesis — the one that suggests targeting those plaques could treat the disease — proved so persistent in the face of almost constant disappointment. We start with a turn-of-the-century discovery by Alois Alzheimer and then weave through the drug industry’s quixotic quest to make a drug out of it, a decades-long endeavor that may finally have come to a close this year.
Watch the video.
We dug through the history, and the answer is a little more complicated than you might think.
Join us for a brief, animated journey through the history of Alzheimer’s research to understand why the amyloid hypothesis — the one that suggests targeting those plaques could treat the disease — proved so persistent in the face of almost constant disappointment. We start with a turn-of-the-century discovery by Alois Alzheimer and then weave through the drug industry’s quixotic quest to make a drug out of it, a decades-long endeavor that may finally have come to a close this year.
Watch the video.
.png)
No hay comentarios:
Publicar un comentario